Comprehensive genomic profiling of esthesioneuroblastoma reveals additional treatment options

Laurie M. Gay, Sungeun Kim, Kyle Fedorchak, Madappa Kundranda, Yazmin Odia, Chaitali Nangia, James Battiste, Gerardo Colon-Otero, Steven Powell, Jeffery Russell, Julia A. Elvin, Jo Anne Vergilio, James Suh, Siraj M. Ali, Philip J. Stephens, Vincent A. Miller, Jeffrey S. Ross

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background. Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant neoplasm of the olfactory mucosa. Despite surgical resection combined with radiotherapy and adjuvant chemotherapy, ENB often relapses with rapid progression. Current multimodality, nontargeted therapy for relapsed ENB is of limited clinical benefit. Materials and Methods. We queried whether comprehensive genomic profiling (CGP) of relapsed or refractory ENB can uncover genomic alterations (GA) that could identify potential targeted therapies for these patients. CGP was performed on formalin-fixed, paraffin-embedded sections from 41 consecutive clinical cases of ENBs using a hybrid-capture, adaptor ligation based next-generation sequencing assay to a mean coverage depth of 593X.The results were analyzed for base substitutions, insertions and deletions, select rearrangements, and copy number changes (amplifications and homozygous deletions). Results. Clinically relevant GA (CRGA) were defined as GA linked to drugs on the market or under evaluation in clinical trials. A total of 28 ENBs harbored GA, with a mean of 1.5 GA per sample. Approximately half of the ENBs (21, 51%) featured at least one CRGA, with an average of 1 CRGA per sample. The most commonly altered gene was TP53 (17%), with GA in PIK3CA, NF1, CDKN2A, and CDKN2C occurring in 7% of samples. Conclusion. We report comprehensive genomic profiles for 41 ENB tumors. CGP revealed potential new therapeutic targets, including targetable GA in the mTOR, CDK and growth factor signaling pathways, highlighting the clinical value of genomic profiling in ENB.

Original languageEnglish (US)
Pages (from-to)834-842
Number of pages9
JournalOncologist
Volume22
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Olfactory Esthesioneuroblastoma
Therapeutics
Olfactory Mucosa
Critical Pathways
p53 Genes
Adjuvant Chemotherapy
Paraffin
Formaldehyde
Ligation
Neoplasms
Intercellular Signaling Peptides and Proteins
Radiotherapy
Clinical Trials
Recurrence

Keywords

  • Comprehensive genomic profiling
  • Esthesioneuroblastoma
  • Everolimus
  • Next-generation sequencing
  • Pazopanib
  • Sunitinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gay, L. M., Kim, S., Fedorchak, K., Kundranda, M., Odia, Y., Nangia, C., ... Ross, J. S. (2017). Comprehensive genomic profiling of esthesioneuroblastoma reveals additional treatment options. Oncologist, 22(7), 834-842. https://doi.org/10.1634/theoncologist.2016-0287

Comprehensive genomic profiling of esthesioneuroblastoma reveals additional treatment options. / Gay, Laurie M.; Kim, Sungeun; Fedorchak, Kyle; Kundranda, Madappa; Odia, Yazmin; Nangia, Chaitali; Battiste, James; Colon-Otero, Gerardo; Powell, Steven; Russell, Jeffery; Elvin, Julia A.; Vergilio, Jo Anne; Suh, James; Ali, Siraj M.; Stephens, Philip J.; Miller, Vincent A.; Ross, Jeffrey S.

In: Oncologist, Vol. 22, No. 7, 01.07.2017, p. 834-842.

Research output: Contribution to journalArticle

Gay, LM, Kim, S, Fedorchak, K, Kundranda, M, Odia, Y, Nangia, C, Battiste, J, Colon-Otero, G, Powell, S, Russell, J, Elvin, JA, Vergilio, JA, Suh, J, Ali, SM, Stephens, PJ, Miller, VA & Ross, JS 2017, 'Comprehensive genomic profiling of esthesioneuroblastoma reveals additional treatment options', Oncologist, vol. 22, no. 7, pp. 834-842. https://doi.org/10.1634/theoncologist.2016-0287
Gay, Laurie M. ; Kim, Sungeun ; Fedorchak, Kyle ; Kundranda, Madappa ; Odia, Yazmin ; Nangia, Chaitali ; Battiste, James ; Colon-Otero, Gerardo ; Powell, Steven ; Russell, Jeffery ; Elvin, Julia A. ; Vergilio, Jo Anne ; Suh, James ; Ali, Siraj M. ; Stephens, Philip J. ; Miller, Vincent A. ; Ross, Jeffrey S. / Comprehensive genomic profiling of esthesioneuroblastoma reveals additional treatment options. In: Oncologist. 2017 ; Vol. 22, No. 7. pp. 834-842.
@article{eb76083ce43c4e7cae213a004f10fa8a,
title = "Comprehensive genomic profiling of esthesioneuroblastoma reveals additional treatment options",
abstract = "Background. Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant neoplasm of the olfactory mucosa. Despite surgical resection combined with radiotherapy and adjuvant chemotherapy, ENB often relapses with rapid progression. Current multimodality, nontargeted therapy for relapsed ENB is of limited clinical benefit. Materials and Methods. We queried whether comprehensive genomic profiling (CGP) of relapsed or refractory ENB can uncover genomic alterations (GA) that could identify potential targeted therapies for these patients. CGP was performed on formalin-fixed, paraffin-embedded sections from 41 consecutive clinical cases of ENBs using a hybrid-capture, adaptor ligation based next-generation sequencing assay to a mean coverage depth of 593X.The results were analyzed for base substitutions, insertions and deletions, select rearrangements, and copy number changes (amplifications and homozygous deletions). Results. Clinically relevant GA (CRGA) were defined as GA linked to drugs on the market or under evaluation in clinical trials. A total of 28 ENBs harbored GA, with a mean of 1.5 GA per sample. Approximately half of the ENBs (21, 51{\%}) featured at least one CRGA, with an average of 1 CRGA per sample. The most commonly altered gene was TP53 (17{\%}), with GA in PIK3CA, NF1, CDKN2A, and CDKN2C occurring in 7{\%} of samples. Conclusion. We report comprehensive genomic profiles for 41 ENB tumors. CGP revealed potential new therapeutic targets, including targetable GA in the mTOR, CDK and growth factor signaling pathways, highlighting the clinical value of genomic profiling in ENB.",
keywords = "Comprehensive genomic profiling, Esthesioneuroblastoma, Everolimus, Next-generation sequencing, Pazopanib, Sunitinib",
author = "Gay, {Laurie M.} and Sungeun Kim and Kyle Fedorchak and Madappa Kundranda and Yazmin Odia and Chaitali Nangia and James Battiste and Gerardo Colon-Otero and Steven Powell and Jeffery Russell and Elvin, {Julia A.} and Vergilio, {Jo Anne} and James Suh and Ali, {Siraj M.} and Stephens, {Philip J.} and Miller, {Vincent A.} and Ross, {Jeffrey S.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1634/theoncologist.2016-0287",
language = "English (US)",
volume = "22",
pages = "834--842",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "7",

}

TY - JOUR

T1 - Comprehensive genomic profiling of esthesioneuroblastoma reveals additional treatment options

AU - Gay, Laurie M.

AU - Kim, Sungeun

AU - Fedorchak, Kyle

AU - Kundranda, Madappa

AU - Odia, Yazmin

AU - Nangia, Chaitali

AU - Battiste, James

AU - Colon-Otero, Gerardo

AU - Powell, Steven

AU - Russell, Jeffery

AU - Elvin, Julia A.

AU - Vergilio, Jo Anne

AU - Suh, James

AU - Ali, Siraj M.

AU - Stephens, Philip J.

AU - Miller, Vincent A.

AU - Ross, Jeffrey S.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background. Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant neoplasm of the olfactory mucosa. Despite surgical resection combined with radiotherapy and adjuvant chemotherapy, ENB often relapses with rapid progression. Current multimodality, nontargeted therapy for relapsed ENB is of limited clinical benefit. Materials and Methods. We queried whether comprehensive genomic profiling (CGP) of relapsed or refractory ENB can uncover genomic alterations (GA) that could identify potential targeted therapies for these patients. CGP was performed on formalin-fixed, paraffin-embedded sections from 41 consecutive clinical cases of ENBs using a hybrid-capture, adaptor ligation based next-generation sequencing assay to a mean coverage depth of 593X.The results were analyzed for base substitutions, insertions and deletions, select rearrangements, and copy number changes (amplifications and homozygous deletions). Results. Clinically relevant GA (CRGA) were defined as GA linked to drugs on the market or under evaluation in clinical trials. A total of 28 ENBs harbored GA, with a mean of 1.5 GA per sample. Approximately half of the ENBs (21, 51%) featured at least one CRGA, with an average of 1 CRGA per sample. The most commonly altered gene was TP53 (17%), with GA in PIK3CA, NF1, CDKN2A, and CDKN2C occurring in 7% of samples. Conclusion. We report comprehensive genomic profiles for 41 ENB tumors. CGP revealed potential new therapeutic targets, including targetable GA in the mTOR, CDK and growth factor signaling pathways, highlighting the clinical value of genomic profiling in ENB.

AB - Background. Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant neoplasm of the olfactory mucosa. Despite surgical resection combined with radiotherapy and adjuvant chemotherapy, ENB often relapses with rapid progression. Current multimodality, nontargeted therapy for relapsed ENB is of limited clinical benefit. Materials and Methods. We queried whether comprehensive genomic profiling (CGP) of relapsed or refractory ENB can uncover genomic alterations (GA) that could identify potential targeted therapies for these patients. CGP was performed on formalin-fixed, paraffin-embedded sections from 41 consecutive clinical cases of ENBs using a hybrid-capture, adaptor ligation based next-generation sequencing assay to a mean coverage depth of 593X.The results were analyzed for base substitutions, insertions and deletions, select rearrangements, and copy number changes (amplifications and homozygous deletions). Results. Clinically relevant GA (CRGA) were defined as GA linked to drugs on the market or under evaluation in clinical trials. A total of 28 ENBs harbored GA, with a mean of 1.5 GA per sample. Approximately half of the ENBs (21, 51%) featured at least one CRGA, with an average of 1 CRGA per sample. The most commonly altered gene was TP53 (17%), with GA in PIK3CA, NF1, CDKN2A, and CDKN2C occurring in 7% of samples. Conclusion. We report comprehensive genomic profiles for 41 ENB tumors. CGP revealed potential new therapeutic targets, including targetable GA in the mTOR, CDK and growth factor signaling pathways, highlighting the clinical value of genomic profiling in ENB.

KW - Comprehensive genomic profiling

KW - Esthesioneuroblastoma

KW - Everolimus

KW - Next-generation sequencing

KW - Pazopanib

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=85024126493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024126493&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2016-0287

DO - 10.1634/theoncologist.2016-0287

M3 - Article

C2 - 28495808

AN - SCOPUS:85024126493

VL - 22

SP - 834

EP - 842

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 7

ER -